Simplify Logo

Full-Time

Staff NGS Application Manager

Confirmed live in the last 24 hours

Ultima Genomics

Ultima Genomics

201-500 employees

High-throughput genomic sequencing services

Healthcare
Biotechnology

Compensation Overview

$135k - $170kAnnually

+ Bonus + Equity + Benefits

Senior, Expert

Fremont, CA, USA

Ability to travel domestically and internationally up to 15%.

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD or equivalent advanced degree in computational biology, molecular biology, or related field is required. Minimum of 5+ years in R&D roles, excluding PhD training
  • Deep understanding of and hands-on experience with genomic technologies, sequencing workflows, and their applications
  • Outstanding leadership skills with a demonstrated ability to work effectively in cross-functional teams, preferably experience in multi-disciplinary R&D teams and collaboration with commercial and sales functions. Excellent communication and presentation abilities are essential
  • A hands-on, proactive approach with a high-energy and positive demeanor that drives results
  • Ability to travel domestically and internationally up to 15%
Responsibilities
  • Coordinate seamlessly with R&D teams to drive the development of new NGS applications. Work closely with manufacturing, quality, and support teams to address product issues and ensure high customer satisfaction
  • Act as the primary interface to ensure alignment between technical advancements and commercial strategies
  • Take full ownership of execution from inception to delivery, ensuring that product goals are met and results are effectively communicated to stakeholders and customers
  • Regularly engage with the commercial team and customers to understand market needs, identify opportunities, assess competitive landscapes, and contribute to strategic decision-making
  • Work with marketing team to develop compelling application notes and application collateral that showcase the unique features and benefits of Ultima’s NGS applications

Ultima Genomics improves human health through advanced genomic sequencing technologies, processing large amounts of genetic data to provide insights into biology and diseases. Its unique sequencing architecture allows for extensive data collection, detection of small genetic variations, and routine testing for early disease detection. This capability gives clients, including researchers and healthcare providers, access to high-quality genomic information. The company's goal is to continuously innovate and expand its services to enable significant advancements in understanding and treating diseases.

Company Stage

Seed

Total Funding

$631.8M

Headquarters

Newark, New Jersey

Founded

2016

Growth & Insights
Headcount

6 month growth

1%

1 year growth

0%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Ultima Genomics' partnerships with organizations like Hartwig Medical Foundation and Genome Insight enhance their capabilities in precision oncology and cancer diagnostics.
  • The commercial launch of the UG 100 system positions Ultima Genomics as a leader in the high-throughput genomics market, potentially driving significant revenue growth.
  • Their continuous innovation and advancements in sequencing technology could lead to groundbreaking discoveries and improvements in human health.

What critics are saying

  • The high cost of developing and maintaining advanced sequencing technologies could strain Ultima Genomics' financial resources.
  • The competitive landscape in the genomics industry is intense, with numerous players vying for market share, which could impact Ultima's growth.

What makes Ultima Genomics unique

  • Ultima Genomics' UG 100 system and ppmSeq technology offer significantly lower sequencing costs and ultra-high accuracy, setting them apart from traditional sequencing technologies.
  • Their focus on making whole genome sequencing affordable and accessible for cancer diagnostics is a unique value proposition in the genomics market.
  • The company's innovative sequencing architecture, featuring an open silicon wafer substrate, enables the $100 genome, a groundbreaking achievement in the industry.